SNIPR Technologies v. Rockefeller University — Federal Circuit Reverses
SNIPR Technologies Limited brought an infringement action against The Rockefeller University before the Federal Circuit, asserting six patents covering sequence-specific antimicrobials and microbiome-altering technology. After 576 days, the Federal Circuit reversed the decision below, marking a significant appellate outcome in the CRISPR-based antimicrobials IP landscape.
Federal Circuit overturns lower ruling in CRISPR antimicrobials dispute
SNIPR Technologies Limited, the plaintiff-appellant, filed this appeal on 15 December 2021 against The Rockefeller University before the Court of Appeals for the Federal Circuit (Case No. 22-1260). The case concerned six US patents — US10524477B2, US10582712B2, US10506812B2, US10463049B2, US20160324938A1, and US10561148B2 — all directed to sequence-specific antimicrobials and the alteration of microbial populations and microbiota.
The recorded basis of termination is 'Case Reversed.' The docket order states: 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: REVERSED.' The Federal Circuit thus found reversible error in the decision from which SNIPR appealed, overturning that lower ruling. The specific grounds for reversal and any remand instructions are not detailed in the available record.
The case closed on 14 July 2023, approximately 576 days after filing — consistent with a substantive Federal Circuit appeal addressing a portfolio of six patents in an emerging biotechnology domain. What drove the reversal, and whether proceedings continue at the trial level, is not disclosed in the publicly available record.
See Complete Case & Patent Analysis →Filing to Case Reversed in 576 days
576 days from filing to Federal Circuit decision — an appeal-level resolution
US10524477B2 — sequence-specific CRISPR antimicrobials portfolio
Any R&D team or product group working on CRISPR-based microbiome modification, sequence-specific antimicrobials, or selective microbial population control should treat this portfolio as a live FTO concern. The Federal Circuit reversal means the lower ruling no longer limits SNIPR's enforcement position, and six overlapping patents covering related aspects of the same technology create a dense claim landscape to navigate. Academic spinouts and commercial biotech alike should assess their exposure.
Official order — verbatim text
The Federal Circuit's order — 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: REVERSED' — is a merits disposition overturning the decision below. The brevity of the recorded order is consistent with a Federal Circuit judgment that may be accompanied by a separate written opinion not captured in the docket summary. The reversal standard at the Federal Circuit requires a finding of legal error; the specific grounds — whether claim construction, validity, or otherwise — are not identified in the available record.
Federal Circuit reverses: what the ruling means for both parties
What 'REVERSED' means at the Federal Circuit
A Federal Circuit reversal means the appellate court found reversible legal error in the decision below — whether a claim construction ruling, a validity determination, or a procedural disposition. The lower decision no longer stands. Depending on the scope of the order, the case may be remanded for further proceedings or ended outright. The specific grounds and any remand instructions are not detailed in the available record.
Lower decision overturnedSNIPR Technologies prevails on appeal
As the appellant securing a reversal, SNIPR Technologies achieves a favourable appellate outcome. The lower ruling that went against SNIPR's position no longer stands. Depending on any remand, SNIPR may have the opportunity to pursue its claims under the corrected legal standard. The enforceability implications of the six asserted patents will depend on proceedings that follow, which are not reflected in the available record.
Appellant wins reversalRockefeller University loses appellate challenge
The Rockefeller University, as appellee, loses the benefit of the lower ruling that had been in its favour. The Federal Circuit's reversal resets the legal position, and Rockefeller may face continued litigation at the trial level if the case is remanded. The specific scope of exposure will depend on the grounds of reversal and any instructions accompanying the order, which are not detailed in the available record.
Appellee loses; lower ruling vacatedReversal strengthens CRISPR antimicrobial patent enforcement risk
A Federal Circuit reversal on a six-patent portfolio covering sequence-specific antimicrobials and microbiota modification signals heightened enforcement risk for companies operating in the CRISPR-based microbiome therapeutics space. Competitors and licensees in this domain should monitor the post-reversal proceedings closely, as the corrected legal standard could widen the scope of enforceable claims against third-party products and research programmes.
CRISPR antimicrobial IP risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | SNIPR Technologies Limited | Company | /Search in Eureka ↗ |
| Defendant | The Rockefeller University | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Brian Robert Matsui | Attorney | Counsel for SNIPR Technologies LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Matthew Ian Kreeger | Attorney | Counsel for SNIPR Technologies LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Parisa Jorjani | Attorney | Counsel for SNIPR Technologies LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Seth W. Lloyd | Attorney | Counsel for SNIPR Technologies LimitedSearch in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster, LLP | Law Firm | Representing SNIPR Technologies LimitedSearch in Eureka ↗ |
| Defendant counsel | Harry Joel Guttman Ph.D. | Attorney | Counsel for The Rockefeller UniversitySearch in Eureka ↗ |
| Defendant counsel | Salvatore J. Arrigo | Attorney | Counsel for The Rockefeller UniversitySearch in Eureka ↗ |
| Defendant law firm | Arrigo, Lee, Guttman, & Mouta-Bellum LLP | Law Firm | Representing The Rockefeller UniversitySearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the CRISPR sequence-specific antimicrobials space
Forward-looking patent and innovation intelligence derived from SNIPR Technologies' portfolio and the competitive landscape around CRISPR-based microbiome and antimicrobial technology.
SNIPR Technologies' CRISPR antimicrobial filing activity
SNIPR Technologies has built a coordinated portfolio of at least six US patents across 2016–2018 application dates covering sequence-specific antimicrobials and microbiota modification. Tracking continuation, divisional, and international counterpart filings from this family will reveal whether SNIPR is expanding claim scope in response to the Federal Circuit's reversal and how broadly the portfolio reaches across jurisdictions.
SNIPR CRISPR portfolioFiling trends in CRISPR-based microbiome modification
The CRISPR microbiome therapeutics space has seen accelerating patent filings from both commercial biotechs and academic institutions. Activity around selective microbial population control and precision antimicrobials is growing, with overlapping claims from multiple assignees. Identifying the density of competing filings around SNIPR's claim space helps assess where design-around opportunities exist and where blocking positions are forming.
CRISPR microbiome filing trendsRockefeller University's CRISPR and antimicrobial patent activity
As a major academic research institution, The Rockefeller University maintains an active patent portfolio in microbiology, phage biology, and related antimicrobial research. Understanding Rockefeller's own CRISPR and antimicrobial filings — and any cross-licensing or technology transfer activity — provides context for the competitive IP dynamics that underpinned this Federal Circuit dispute and the post-reversal landscape.
Rockefeller IP positionAdjacent innovation opportunities near SNIPR's claim landscape
SNIPR's portfolio focuses on sequence-specific targeting within microbial populations. Adjacent areas — including delivery mechanisms for CRISPR antimicrobials, non-CRISPR sequence-specific approaches, and next-generation microbiome modulation platforms — may represent lower-density IP white space for R&D investment. Mapping claim boundaries around US10524477B2 and related patents identifies where innovators can build without entering SNIPR's enforced territory.
Antimicrobial IP white spaceSimilar CRISPR antimicrobial patent appeals at the Federal Circuit
Explore Federal Circuit appeals involving CRISPR-based antimicrobials, microbiome modification patents, and related biotechnology infringement actions similar to SNIPR v. Rockefeller.
What this case signals for the CRISPR antimicrobials IP landscape
A Federal Circuit reversal on a six-patent CRISPR antimicrobial portfolio has broad implications for biotech IP strategy and microbiome therapeutics development.
Federal Circuit reversal reactivates enforcement risk across six CRISPR patents
Companies developing sequence-specific antimicrobials or microbiota-modifying platforms should reassess their freedom-to-operate position. SNIPR's reversal win means the lower ruling shielding Rockefeller no longer stands, and the corrected legal standard may widen claim scope. Monitoring post-remand proceedings is now a priority for any player in this space.
Six-patent portfolio signals SNIPR's broad IP strategy in CRISPR microbiome space
SNIPR Technologies asserting six patents across related application numbers suggests a layered filing strategy designed to cover multiple facets of sequence-specific antimicrobial technology. R&D teams working on phage-based or CRISPR-based microbiome interventions should map their pipeline against this portfolio to identify overlap before committing further development resources.
SNIPR v Rockefeller — key questions answered
The Federal Circuit reversed the decision below in Case No. 22-1260, entering judgment 'ORDERED AND ADJUDGED: REVERSED' on 14 July 2023. The recorded basis of termination is 'Case Reversed.' The specific grounds for the reversal and any remand instructions are not detailed in the publicly available case record.
SNIPR Technologies asserted six US patents: US10524477B2, US10582712B2, US10506812B2, US10463049B2, US20160324938A1, and US10561148B2. All relate to sequence-specific antimicrobials and the alteration of microbial populations and microbiota. The application numbers indicate filings across 2015–2018.
The reversal means the lower ruling that was unfavourable to SNIPR no longer stands. SNIPR's six-patent portfolio covering sequence-specific antimicrobials is no longer constrained by the overturned decision. Depending on whether the matter is remanded, SNIPR may be able to pursue its claims under the corrected legal standard, elevating enforcement risk for third parties in the CRISPR antimicrobial and microbiome modification space.
A reversal on a six-patent portfolio covering CRISPR-based sequence-specific antimicrobials strengthens SNIPR's IP position and signals that these patent claims survived a significant appellate challenge. Companies and academic institutions developing microbiome-modifying or sequence-targeted antimicrobial technologies should reassess their freedom-to-operate analyses in light of the reinstated legal position.
The appeal was filed on 15 December 2021 and closed on 14 July 2023, a duration of 576 days. This is consistent with a substantive Federal Circuit appeal involving a multi-patent portfolio in a complex biotechnology domain, likely requiring full briefing, oral argument, and a written decision.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.